Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

Recruiting

Phase 2

VTX3232 & SemaglutidePhase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

Sponsor:

Zomagen Biosciences Ltd.

Code:

NCT06771115

Conditions

Obesity

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

VTX3232 Dose A

Placebo

VTX3232 Dose A in combination with semaglutide

Placebo in combination with semaglutide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Zomagen Biosciences Ltd. on 2025-04-24.